Interactions Between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831623

Authors

Selin Oncul

Min Soon Cho

Affiliations

Soon will be listed here.

Abstract

Platelets, the primary operatives of hemostasis that contribute to blood coagulation and wound healing after blood vessel injury, are also involved in pathological conditions, including cancer. Malignancy-associated thrombosis is common in ovarian cancer patients and is associated with poor clinical outcomes. Platelets extravasate into the tumor microenvironment in ovarian cancer and interact with cancer cells and non-cancerous elements. Ovarian cancer cells also activate platelets. The communication between activated platelets, cancer cells, and the tumor microenvironment is via various platelet membrane proteins or mediators released through degranulation or the secretion of microvesicles from platelets. These interactions trigger signaling cascades in tumors that promote ovarian cancer progression, metastasis, and neoangiogenesis. This review discusses how interactions between platelets, cancer cells, cancer stem cells, stromal cells, and the extracellular matrix in the tumor microenvironment influence ovarian cancer progression. It also presents novel potential therapeutic approaches toward this gynecological cancer.

Citing Articles

Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging.

Ryu J, Jeong Y, Lee S, Choi Y Cancers (Basel). 2025; 17(3).

PMID: 39941717 PMC: 11815719. DOI: 10.3390/cancers17030345.

Clinically relevant body composition phenotypes are associated with distinct circulating cytokine and metabolomic milieus in epithelial ovarian cancer patients.

Davis E, Hsiao H, Barone N, Rosario S, Cannioto R Front Immunol. 2024; 15:1419257.

PMID: 39575261 PMC: 11578747. DOI: 10.3389/fimmu.2024.1419257.

Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer.

Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D Biomolecules. 2024; 14(8).

PMID: 39199316 PMC: 11352941. DOI: 10.3390/biom14080928.

Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour.

Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D Cancers (Basel). 2024; 16(13).

PMID: 39001418 PMC: 11240748. DOI: 10.3390/cancers16132356.

References

Meikle C, Meisler A, Bird C, Jeffries J, Azeem N, Garg P . Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis. PLoS One. 2020; 15(8):e0236966. PMC: 7416940. DOI: 10.1371/journal.pone.0236966. View

Kehrl J, Thevenin C, Rieckmann P, Fauci A . Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991; 146(11):4016-23. View

Sun C, Feng S, Cao Z, Bei J, Chen Q, Zhao W . Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells Mediates Platelet Microvesicle-Induced Angiogenesis. Cell Physiol Biochem. 2017; 41(6):2319-2332. DOI: 10.1159/000475651. View

Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View

Pavlovic N, Rani B, Gerwins P, Heindryckx F . Platelets as Key Factors in Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(7). PMC: 6678690. DOI: 10.3390/cancers11071022. View

Chignard M, Le Couedic J, Tence M, Vargaftig B, Benveniste J . The role of platelet-activating factor in platelet aggregation. Nature. 1979; 279(5716):799-800. DOI: 10.1038/279799a0. View

Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E . Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151(7):1542-56. DOI: 10.1016/j.cell.2012.11.024. View

Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K . Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol. 2008; 68(3):328-36. DOI: 10.1111/j.1365-3083.2008.02139.x. View

10.

Ye B, Li F, Chen M, Weng Y, Qi C, Xie Y . A panel of platelet-associated circulating long non-coding RNAs as potential biomarkers for colorectal cancer. Genomics. 2021; 114(1):31-37. DOI: 10.1016/j.ygeno.2021.11.026. View

11.

Hasegawa S, Pawankar R, Suzuki K, Nakahata T, Furukawa S, Okumura K . Functional expression of the high affinity receptor for IgE (FcepsilonRI) in human platelets and its' intracellular expression in human megakaryocytes. Blood. 1999; 93(8):2543-51. View

12.

Zeng X, Xie H, Yuan J, Jiang X, Yong J, Zeng D . M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019; 20(7):956-966. PMC: 6606001. DOI: 10.1080/15384047.2018.1564567. View

13.

Motohashi K, Shibata S, Ozaki Y, Yatomi Y, Igarashi Y . Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett. 2000; 468(2-3):189-93. DOI: 10.1016/s0014-5793(00)01222-9. View

14.

Ma C, Fu Q, Diggs L, McVey J, McCallen J, Wabitsch S . Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022; 40(9):986-998.e5. PMC: 9474605. DOI: 10.1016/j.ccell.2022.08.004. View

15.

Denizot Y, Guglielmi L, Donnard M, Trimoreau F . Platelet-activating factor and normal or leukaemic haematopoiesis. Leuk Lymphoma. 2003; 44(5):775-82. DOI: 10.1080/1042819031000067549. View

16.

Raiden S, Schettini J, Salamone G, Trevani A, Vermeulen M, Gamberale R . Human platelets produce granulocyte-macrophage colony-stimulating factor and delay eosinophil apoptosis. Lab Invest. 2003; 83(4):589-98. DOI: 10.1097/01.lab.0000062851.71286.47. View

17.

Angiari S, Rossi B, Piccio L, Zinselmeyer B, Budui S, Zenaro E . Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. J Immunol. 2013; 191(11):5489-500. PMC: 4627945. DOI: 10.4049/jimmunol.1301235. View

18.

Chatterjee M, Rath D, Gawaz M . Role of chemokine receptors CXCR4 and CXCR7 for platelet function. Biochem Soc Trans. 2015; 43(4):720-6. DOI: 10.1042/BST20150113. View

19.

Lim L, Bui H, Farrelly O, Yang J, Li L, Enis D . Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC. Blood. 2019; 134(20):1764-1775. PMC: 6856989. DOI: 10.1182/blood.2019001736. View

20.

da Silva Junior I, Stone S, Rossetti R, Jancar S, Lepique A . Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor. J Immunol Res. 2018; 2017:5482768. PMC: 5763242. DOI: 10.1155/2017/5482768. View